Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

13 treatments under study, led by Antithymocyte Globulin

Research Leaders

15 sponsors active, led by Zhejiang University

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 9 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
Phase 1/2 (1)
Phase 2 (2)
Phase 3 (2)

Trial Status

Completed3
Recruiting3
Unknown2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07662382Not Yet Recruiting

Cousin vs. Sibling Donors in Haplo-HSCT

NCT05166967Phase 3CompletedPrimary

Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

NCT05622032CompletedPrimary

Blood Virome After Haploidentical Hematopoietic Stem Cell Transplantation, a Pilot Study

NCT06041893RecruitingPrimary

Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

NCT06423131Not ApplicableRecruiting

Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

NCT06381817Phase 3Recruiting

Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients

NCT04778618Phase 2UnknownPrimary

Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

NCT03236220Phase 2CompletedPrimary

Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation

NCT02014506Phase 1/2UnknownPrimary

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Showing all 9 trials

Research Network

Common Treatments

  • Antithymocyte Globulin3
  • Haplocord Hct1
  • Fludarabine1
  • Haplohct1
  • Acetylcysteine1

Active Sponsors

  • Zhejiang University2
  • Chinese PLA General Hospital2
  • Nanfang Hospital, Southern Medical University2
  • The First Affiliated Hospital of Soochow University2
  • Peking University People's Hospital2

Top Investigators

Related Conditions

  • Nonmalignant Disease1
  • Acute T Cell Lymphoblastic Leukemia1
  • Hematopoietic Malignancies1
  • Donor1
  • Cord Blood1

Activity Timeline